ONKURE THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax
ONKURE THERAPEUTICS, INC. (OKUR) reported Other Comprehensive Income (Loss), Net of Tax of -$13.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$13.00K.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $15.00K, a 50.00% increase year-over-year.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$1.00K.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$20.00K, a 136.36% decline year-over-year.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $51.00K.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$77.00K, a 326.47% decline from fiscal 2021.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2021 was $34.00K.
- ONKURE THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2020 was -$3.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.00K 10-Q · filed 2026-08-04 | |||
| 2024-09-30 | $15.00K 10-Q · filed 2024-11-07 | $14.00K derived: sum of 2 quarters · filed 2024-11-07 | -$6.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2024-06-30 | -$1.00K 10-Q · filed 2024-11-07 | -$21.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2024-03-31 | -$20.00K 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $51.00K 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-07 | -$33.00K derived: sum of 2 quarters · filed 2024-11-07 | $22.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$43.00K 10-Q · filed 2024-11-07 | $12.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $55.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$77.00K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$194.00K 10-Q · filed 2023-11-13 | -$90.00K derived: sum of 2 quarters · filed 2023-11-13 | -$60.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $104.00K 10-Q · filed 2023-11-13 | $134.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $30.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $34.00K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $12.00K 10-Q · filed 2022-11-08 | $17.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $5.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | -$3.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |